<p>Clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis</p>

Abstract

Objective: Our objective was to conduct a meta-analysis to investigate the clinicopathological features and prognostic value of programmed cell death ligand 1 (PD-L1) expression in patients with urothelial carcinoma (UC). Materials and methods: Twenty-seven studies with 4,032 patients were included in the meta-analysis. Pooled ORs and 95% CIs were used to examine the associations between clinical factors and PD-L1 expression. HRs and 95% CIs were extracted from eligible studies. Heterogeneity was evaluated using the chi-squared-based Q test and I 2 statistic. Results: Expression of PD-L1 on tumor cells (TCs) was associated with muscle-invasive disease (OR=3.67, 95% CI: 2.53–5.33), and inversely associated with the history of intravesical bacilli Calmette-Guerin therapy (OR=0.39, 95% CI: 0.18–0.82) in bladder cancer patients. PD-L1 expression on TCs was associated with worse overall survival (HR=2.06, 95% CI: 1.38–3.06) in patients with organ-confined bladder cancer. PD-L1 expression in patients with UC was significantly related to better objective response rate after PD-1/PD-L1 antibody treatment. Conclusions: Expression of PD-L1 on TCs was associated with muscle-invasive disease in patients with bladder cancer. Patients with PD-L1-positive UC had a significantly better response to PD-1/PD-L1 targeted treatment.

Pathological roles of c‑Met in bladder cancer: Association with cyclooxygenase‑2, heme oxygenase‑1, vascular endothelial growth factor‑A and programmed death ligand�1

“…However, there have been no studies on such interrelations among COX-2, VEGF-A, and PD-L1 in human BC tissues, but previous results support our findings on the correlations among these cancer-related molecules. Moreover, our univariate analyses suggested that muscle invasion and metastasis in BC are regulated by complex mechanisms comprising COX-2, HO-1, VEGF-A, and PD-L1, and this opinion is supported by many previous reports (7,19,(35)(36)(37). However, interestingly, our multivariate analyses demonstrated that muscle invasion was independently associated with COX-2 expression and that metastasis was associated with PD-L1 expression, whereas HO-1 and VEGF-A were not associated with either muscle invasion or metastasis.…”

PD-L1 Expression in Muscle-Invasive Urinary Bladder Urothelial Carcinoma According to Basal/Squamous-Like Phenotype

“…But, PD-L1 expression on clinical prognosis is poorly defined in UC. Some studies have suggested that PD-L1 overexpression was correlated with poor prognosis in bladder cancer (25)(26)(27). On the other hand, some studies reported that PD-L1 expression has no correlation with clinical outcome in UC (28,29).…”

Chemotherapy Plus Immune Check-Point Inhibitors in Metastatic Bladder Cancer

“…Nowadays, it is suggested that PD-L1 expression in bladder cancer cells is associated with more aggressive clinical features and lower OS in patients with metastatic dis-ease. Regarding PD-1 / PD-L1 targeted treatment in patients with mUC it is known that, although the benefit is greater in patients with positive PD-L1, patients with negative PD-L1 may also respond to anti-PD-1 therapy [28]. Therefore, a more useful marker is needed to determine the appropriate patient for antiPD-1/PD-L1 therapy.…”